Compare INGN & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INGN | SPRO |
|---|---|---|
| Founded | 2001 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.5M | 156.3M |
| IPO Year | 2013 | 2017 |
| Metric | INGN | SPRO |
|---|---|---|
| Price | $6.54 | $2.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $11.25 | N/A |
| AVG Volume (30 Days) | 224.6K | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 43.42 | ★ 111.81 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $348,668,000.00 | $66,802,000.00 |
| Revenue This Year | $8.03 | N/A |
| Revenue Next Year | $7.76 | $300.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 3.86 | ★ 39.24 |
| 52 Week Low | $5.34 | $1.80 |
| 52 Week High | $9.13 | $3.08 |
| Indicator | INGN | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 49.53 | 38.15 |
| Support Level | $6.00 | $1.93 |
| Resistance Level | $6.72 | $2.45 |
| Average True Range (ATR) | 0.26 | 0.11 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 33.33 | 29.60 |
Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.